10th World Congress on Gastrointestinal Cancer -- Barcelona, Spain

June 19, 2008

As it celebrates its 10th year, the ESMO International Symposium: 10th World Congress on Gastrointestinal Cancer® has received endorsements from 6 leading professional societies and organizations, solidifying the reputation of the Congress as the premier platform for specialists in cancer research, leading oncologists and practicing clinicians to review the state-of-the-art in gastrointestinal cancer and share the latest information on its multidisciplinary management. The European Neuroendocrine Tumor Society (ENETS), European Oncology Nursing Society (EONS), European Organisation for Research and Treatment of Cancer (EORTC): Gastrointestinal Tumor Group, European School of Oncology (ESO), European Society of Surgical Oncology (ESSO), and Europacolon have indicated their support for the high quality of the scientific agenda and its educational value to oncology professionals. The European Society for Medical Oncology (ESMO) began its association with the Congress in 2005, and in 2008 brought the Congress under its educational wing as a partnership meeting.

In recognition of its 10 year history, Congress co-chair Eric Van Cutsem observed "We have much to celebrate from the past years. The number of deaths from colorectal cancer has been dropping as treatment has improved, allowing for more effective options for people with this diagnosis. However, there is still much work to be done. We are proud of our tradition of excellence in educating the medical community and look forward to continuing the journey."

The ESMO International Symposium: 10th World Congress on Gastrointestinal Cancer®, developed and managed by Imedex, begins next week in Barcelona, Spain, running from 25-28 June 2008. More than 3,300 healthcare providers from nearly 100 countries are expected to attend. The internationally recognized faculty will include 68 experts, chaired by Mario Dicato, MD of the Luxembourg Medical Center in Luxembourg and Eric Van Cutsem, MD, PhD of the University Hospital Gasthuisberg in Leuven, Belgium.

Designed to promote a multidisciplinary approach to treatment, the scientific agenda offers targeted sessions for oncology surgeons and nurses as well as a comprehensive range of topics for researchers, gastroenterologists, and medical and radiation oncologists. Presentation of cutting edge research has become one of the highlights of the Congress, as more than 400 abstracts have been accepted for publication in a special supplement of Annals of Oncology.
-end-
About Imedex

Imedex, LLC is an industry leader in providing accredited, independent continuing medical education (CME) worldwide. Imedex develops high quality, scientific programs that translate the latest research into clinically relevant information, improving patient care through education. The programs have a proven sustained impact on disease management, exceptional organization, and outstanding educational value. With 13,000 live meeting attendees and 120,000 e-learning experiences annually, Imedex educates the global healthcare community. Live, enduring, and e-learning programs focus on impacting the clinical management of patients around the world in the therapy areas of oncology, hematology, gastroenterology, infectious disease, urology, and psychiatry. Attendees consistently rate Imedex programs as excellent in terms of scientific quality, execution, and educational value.

For more information about Imedex, visit www.imedex.com.

About the European Society for Medical Oncology (ESMO)

The European Society for Medical Oncology (ESMO) is the leading European non-profit, professional organization for medical oncology with a focus on promoting multidisciplinary cancer treatment around the world. ESMO unites medical oncologists, oncology specialists, healthcare professionals, caregivers, patients and policy makers in a global alliance committed to eradicating cancer and ensuring equal access to high quality treatment for all patients. Thanks to its state-of-the-art education and training programs, ESMO plays an instrumental role in providing the oncology community with the most up-to-date scientific research and information available. Through its flagship journal, Annals of Oncology, ESMO publishes articles on all aspects of clinical oncology. ESMO is dedicated to educating and supporting oncologists, optimizing patient care, disseminating cancer-specific information to the public, and advocating patient rights. As an authoritative voice in the fight against cancer, ESMO provides both the platform and the consultative expertise to influence national and international organizations as well as European authorities, in order to establish common standards for a multidisciplinary approach to cancer treatment.

For more information about ESMO, visit www.esmo.org

European Society for Medical Oncology

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.